Skip to main content
Clinical Trials/NCT01962623
NCT01962623
Completed
Not Applicable

Interpersonal Psychotherapy for Youth With Severe Mood Dysregulation- Randomized Trial

Johns Hopkins University1 site in 1 country31 target enrollmentAugust 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Severe Mood Dysregulation
Sponsor
Johns Hopkins University
Enrollment
31
Locations
1
Primary Endpoint
Retention rate
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to determine the feasibility and acceptability of utilizing an adapted form (i.e. IPT-MBD) of a psychosocial intervention, Interpersonal Psychotherapy for Depressed Adolescents, for youth with severe mood dysregulation (SMD) or disruptive mood dysregulation disorder (DMDD).

The investigators hypothesize that retention rates will be >80%, satisfaction scores will average 6 (high) on a 7 point satisfaction scale, and that youth who receive the IPT intervention will have overall improvement in SMD/DMDD symptoms.

Detailed Description

This research is being done to learn more about how to help teenagers with a sad or angry mood, and emotional responses out of proportion to what would be expected in a situation. Together these symptoms are called Severe Mood Dysregulation (SMD), a research diagnosis, or disruptive mood dysregulation disorder (DMDD), a newer clinical diagnosis. Currently, there is no standard treatment for teens that have SMD/DMDD. These teens usually receive medication and some type of talk therapy. This research is being done to compare two types of talk therapy to see which is most effective in helping teens with SMD/DMDD. Investigators will compare treatment as usual (TAU) with Interpersonal Psychotherapy for Youth with Mood and Behavior Dysregulation (IPT-MBD). Investigators do not know if TAU and IPT-MBD work just as well, or if one is better than the other. When this study is over, investigators hope there will be a better idea of how to study treatments for teens with SMD/DMDD. For those participants who receive IPT-MBD, are prescribed an antipsychotic, and have significant improvement in symptoms, investigators will gradually taper the antipsychotic dose.

Registry
clinicaltrials.gov
Start Date
August 2013
End Date
October 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Leslie Miller, M.D.

Assistant Professor

Johns Hopkins University

Eligibility Criteria

Inclusion Criteria

  • Male and female subjects, ages 12 to 17 years, who meet criteria for severe mood dysregulation (SMD) as defined by NIMH criteria or for disruptive mood dysregulation disorder (DMDD).
  • Subject has an estimated IQ \>70 on the Kaufman Brief Intelligence Test (KBIT-
  • Subjects will have continuously resided with a legal guardian who has known the adolescent well for at least one year before study entry and is legally able to sign the consent form.
  • Children's Global Assessment Scale (CGAS) ≤ 60
  • CGI-S (SMD) ≥ 4
  • Participant and guardian must agree to have therapy sessions audiotaped for training purposes.

Exclusion Criteria

  • Subject poses a significant risk for dangerousness to self or others. Risk will be determined by clinical history, clinical diagnostic interview and KSADS-PL interview of parent and patient by clinician.
  • Subject suffers from a concomitant medical or psychiatric comorbidity that makes this study protocol inadvisable (either the treatment is contraindicated or the disorder is not the primary focus of treatment).
  • Subject meets DSM-IV criteria for current alcohol or substance dependence or current use (defined as the past 4 weeks).
  • Primary caretaker does not speak English or is not capable of completing study measures.
  • Pregnant females.

Outcomes

Primary Outcomes

Retention rate

Time Frame: 24 weeks

To describe/assess feasibility of IPT-MBD, investigators will look at ease of recruitment and retention rate goal of at least 80%. Investigators will collect data on the number of subjects recruited, enrolled, and who followed the protocol for 24 weeks. Investigators will comment on adherence to the overall study, as well as to specific treatment visits.

Secondary Outcomes

  • Satisfaction(24 weeks)
  • Clinical Global Impressions Scale for SMD/DMDD (CGI-SMD/DMDD)(24 weeks)

Study Sites (1)

Loading locations...

Similar Trials